Two important themes for future clinical research in the neuropsychology of epilepsy are proposed: (1) the neurobiological abnormalities that underlie neuropsychological impairment in people with epilepsy, and (2) neuropsychological status of persons with new-onset epilepsy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yebeh.2011.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-language neuropsychological measures increase sensitivity of identifying language reorganization in patients with epilepsy: a pilot study.
J Clin Exp Neuropsychol
January 2025
Department of Neurology, Medical University of South Carolina, Charleston, USA.
Objective: To examine neuropsychological characteristic differences between typical and atypical language dominance in adult persons with epilepsy (PWE) and mesial temporal sclerosis (MTS), including exploring the impact of selected clinical variables on detection of atypical language and neuropsychological performance.
Methods: Adults with intractable epilepsy and MTS ( = 39) underwent comprehensive, pre-surgical evaluation including fMRI and neuropsychological assessment. Participants with concordant lateralization of MTS and seizure onset were included.
Long-term memory plasticity in a decade-long connectivity study post anterior temporal lobe resection.
Nat Commun
January 2025
Department of Clinical and Experimental Epilepsy, Queen Square Institute of Neurology, UCL, London, WC1N 3BG, UK.
Approximately 40% of individuals undergoing anterior temporal lobe resection for temporal lobe epilepsy experience episodic memory decline. There has been a focus on early memory network changes; longer-term plasticity and its impact on memory function are unclear. Our study investigates neural mechanisms of memory recovery and network plasticity over nearly a decade post-surgery.
View Article and Find Full Text PDFNegative impact of self-reported executive problems in patients with functional/dissociative seizures: Results from a prospective long-term observational study.
Seizure
January 2025
The National Centre for Epilepsy, Division of Clinical Neuroscience, Full Member of European Reference Network on Rare and Complex Epilepsies EpiCARE, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Objective: Functional/dissociative seizures (FDS) are common and pose a considerable burden on both individual patients and healthcare systems. Cognitive complaints are frequent in patients with FDS. Previous studies on cognitive function in patients with FDS have yielded mixed results.
View Article and Find Full Text PDFAnterior prefrontal EEG theta activities indicate memory and executive functions in patients with epilepsy.
Epilepsia
January 2025
Brain and Mind Electrophysiology Laboratory, Multimedia Systems Department, BioTechMed Center, Gdansk University of Technology, Gdansk, Poland.
Objective: Cognitive deficits are one of the most debilitating comorbidities in epilepsy and other neurodegenerative, neuropsychiatric, and neurodevelopmental brain disorders. Current diagnostic and therapeutic options are limited and lack objective measures of the underlying neural activities. In this study, electrophysiological biomarkers that reflect cognitive functions in clinically validated batteries were determined to aid diagnosis and treatment in specific brain regions.
View Article and Find Full Text PDFThe Feasibility of Personalized Endpoints in Assessing Treatment Outcomes in Rare Disease: A Pilot Study of Goal Attainment Scaling in SCN2A-Associated Developmental Epileptic Encephalopathy.
Value Health
December 2024
FamilieSCN2A Foundation, E. Longmeadow, MA, USA; Decoding Developmental Epilepsies - DEE-P Connections; Washington, DC, USA; Northwestern Feinberg School of Medicine, Dept. Neurology, Chicago, IL, USA.
Objectives: For individuals living with rare neurodevelopmental disorders, especially those who are at the most severe end of the spectrum, standardized outcome measures may lack the sensitivity to capture small but meaningful changes. Personalized endpoints such as Goal Attainment Scaling (GAS) allow the assessment of treatment response across variable baseline states and disease manifestations and thus provide a highly sensitive measure of efficacy. The current study tested the feasibility of using GAS in rare SCN2A-associated developmental and epileptic encephalopathy (SCN2A-DEE).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!